Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07300163

FeetSee Thermal Images Collection Protocol in Diabetes Patients

FeetSee Thermal Images Collection Protocol in Diabetes Patients — Recruiting • Cardiology / Cardiovascular • NCT07300163.

📅 22 Jun 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07300163
Sponsor
Diabetis JSC
Start
2025-12-16
ClinicaliQ Trial Snapshot
  • FeetSee Thermal Images Collection Protocol in Diabetes Patients — Recruiting • Cardiology / Cardiovascular • NCT07300163.
  • What is being tested: FeetSee thermal imaging technology is being evaluated as a potential early detection tool for diabetic foot ulcers by collecting thermal images to identify temperature changes that may indicate developing foot complications before visible ulcers appear.
  • Patient eligibility overview: The trial includes adults with diabetes mellitus who have or are at risk of developing diabetic peripheral neuropathy and foot ulcers, enabling assessment of the imaging tool across the spectrum of diabetic foot disease.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Diabetic foot ulcers (DFUs) are a major cause of morbidity, lower-extremity amputation and healthcare costs in people with diabetes. DFUs often develop without pain or warning symptoms because of diabetic peripheral neuropathy, so patients may not recognise early signs of tissue damage. Monitoring plantar foot skin temperature is a promising strategy to detect early "hot-spots" of inflammation that precede ulceration and could trigger timely preventive action. This prospective, single-group study will enrol adults with type 1 or type 2 diabetes, a history of plantar DFU that has been healed for…

Eligibility Snapshot
  • : * Males/females aged over 18 years. * Type 1 or type 2 diabetes. * History of plantar diabetic foot ulcer(s). * Foot ulcer healed for at least 6 weeks before entry into study, as determined by a specialist healthcare provider. * Presence of diabetic peripheral neuropathy defined by either of the following: * Inability to detect the monofilament (10g) applied at two foot sites, including the apex of the Hallux (ADA guidelines 2008 Diabetes Care 31(1)). * A Vibration Perception Threshold (VPT) >20V, and/or by inability to detect application of the monofilament at the apex of the Hallux. * Presence of at least one palpable foot pulse.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Clinical Brief
Meet the teenagers calling for action on violence against women and girls
Cardiology / Cardiovascular · BBC Health · 28 Jul 2026
Teenage activists are mobilising public engagement on violence against women and girls (VAWG), highlighting widespread concern among younger generations about this health…
View brief →
Clinical Brief
New heart disease and strokes plan to saves thousands of lives
Cardiology / Cardiovascular · NHS England · 07 Jul 2026
A new national framework aims to reduce premature deaths from heart disease and strokes by 25% over the next decade, requiring implementation…
View brief →
Guideline
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Cardiology / Cardiovascular · 05 Aug 2026
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated…
View guideline →